Lack of impact of protease inhibitor resistance-associated mutations on the outcome of HIV-1-infected patients switching to darunavir-based dual therapy

Autor: Vizcarra, P, Blanco, JL, Montejano, R, Negredo, E, Espinosa, N, Casado, JL, Monsalvo, M, Bernardino, JI, Puig, J, Montero, M, Castro, I, Mena, A, Castro, A, Palacios, R, de Quiros, JCLB, Tejerina, F, Latorre, LP, Ramirez, M, Vergas, J, Tellez, MJ, Galindo, P, Vilalta, RF, Cabello, A, Deltoro, MG, Cuevas, PR, de Santiago, AD, Moral, SD

Publikováno v: Infectious Diseases
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
INFECTIOUS DISEASES
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe

Background: Little is known about the impact of baseline resistance-associated mutations (RAMs) on the outcomes of alternative therapeutic strategies such as dual regimens. We assessed the efficacy of boosted darunavir plus raltegravir (DRV + RAL) du

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1e2535bd73d606feaf8bc26867272692
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1329